DRTS (Alpha Tau Medical) ROCE %: -55.05% (As of Mar. 2026)


DRTS Alpha Tau Medical Ltd DRTS
28 GF Score
Price $13.22
! 3 Warning Signs
View Full Analysis

What is Alpha Tau Medical ROCE %?

Alpha Tau Medical DRTS +4.67% 28 ROCE % is -55.05% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alpha Tau Medical's annualized ROCE % for the quarter that ended in Mar. 2026 was -55.05%.

Alpha Tau Medical  (NAS:DRTS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alpha Tau Medical ROCE % Related Terms

Alpha Tau Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Alpha Tau Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Tau Medical ROCE % Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -61.47 -43.93 -26.90 -35.36 -48.83

Alpha Tau Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.08 -42.20 -45.18 -52.33 -55.05
DRTS
28GF Score
Alpha Tau Medical Ltd DRTS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Tau Medical ROCE % Calculation

Alpha Tau Medical's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-42.159/( ( (86.204 - 8.675) + (105.652 - 10.507) )/ 2 )
=-42.159/( (77.529+95.145)/ 2 )
=-42.159/86.337
=-48.83 %

Alpha Tau Medical's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-53.252/( ( (105.652 - 10.507) + (108.773 - 10.448) )/ 2 )
=-53.252/( ( 95.145 + 98.325 )/ 2 )
=-53.252/96.735
=-55.05 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -55.05% mean?
Alpha Tau Medical (DRTS) has a ROCE % of -55.05% as of Mar. 2026.
Is Alpha Tau Medical's ROCE % too high?
Alpha Tau Medical's current ROCE % is -55.05%. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's ROCE % compare to ORIC and OLMA?
Alpha Tau Medical's ROCE % of -55.05% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Alpha Tau Medical's current ROCE % is -55.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current ROCE % of -55.05%. The current ROCE % is -55.05%. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current ROCE % is -55.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Tau Medical Business Description

Address Kiryat HaMada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score

Get the complete analysis for DRTS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.22
Price